Phosplatin Therapeutics has engaged in research and development activities with collaborators in thirteen countries.
Our relationships within the pharmaceutical industry, with U.S. and European universities, and with contract research organizations cover translational research activities, clinical development, as well as manufacturing and analytical method development for PT-112, our lead agent in oncology therapeutics.
Following approval of the Investigational New Drug (IND) application for PT-112, we began first-in-human clinical studies at the MD Anderson Cancer Center in Houston, Texas, and at three other U.S. sites.
To learn more about the Ongoing U.S. Phase I study in solid tumors, please visit the link below:
To learn more about the combination study of PT-112 in taiwan, please visit the separate link below: